Inflammation in hypertension: Primary evidence

Chinese Medical Journal

Volumn 119, Issue 14, 2006, Pages 1215-1221

  Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Hypertension; Inflammation; Pathogenesis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; MACROLIDE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; VALSARTAN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; GENETIC RISK; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATORY DISEASE; INSULIN RESISTANCE; MATERNAL HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RISK ASSESSMENT; RISK FACTOR; TARGET ORGAN;

EID: 33746350176     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200607020-00016     Document Type: Article

References (39)

1. Grundy SM. Inflammation, hypertension, and the metabolic syndrome. JAMA 2003; 290: 3000-3002.
2. Li JJ, Fang CH, Hui RT. Is hypertension an inflammatory disease? Med Hypotheses 2005; 64:236-240.
3. Teran E, Escudero C, Moya W, Calle A. Markers of chronic inflammation in normal pregnancy and pre-eclampsia. Br J Obstet Gynecol 2000; 17: 201-208.
4. Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressure. J Hypertens 2003; 21:1841-1846.
5. Dorffel Y, Latsch C, Stuhlmuller B, Schreiber S, Scholze S, Barmester GR. Preactivation peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34:113-117.
6. Hilgers KF. Monocytes/macrophages in hypertension. J Hypertens 2002; 20:593-596.
7. Sasso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951.
8. Bautista LE, Lopez-Jaramillo P, Vera LM, Cases JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19:857-861.
9. Li JJ, Fang CH. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses 2004; 63: 100-102.
10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
11. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses 2004; 62: 499-506.
12. Li JJ. Silent myocardial ischemia may be related to inflammatory response. Med Hypotheses 2004; 62:252-256.
13. Li JJ. Inflammation: an important mechanism for different clinical settings of coronary artery disease. Chin Med J 2005; 118:1817-1826.
14. Dzielak DJ. The immune system and hypertension. Hypertension 1992; 19:36-44.
15. Bataillard A, Renaudin C, Sassard J. Silica attenuates hypertension in Lyon hypertensive rats. J Hypertens 1995; 13:1581-1584.
16. Schmid-Schonbein GW, Seiffge D, Delano FA, Shen K, Zweifach BW. Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension 1991; 17: 323-330.
17. McCarron RM, Wang L, Siren AL, Spatz M, Hallenbeck JM. Monocyte adhesion to cerebromicrovascular endothelial cells derived from hypertensive and normotensive rats. Am J Physiol 1994; 267: H2491-H2497.
18. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension 1991; 18:132-141.
19. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19:464-474.
20. Haller H, Behrend M, Park JK, Schaberg T, Luft FC, Distler A. Monocyte infiltration and c-fms expression in hearts of spontaneously hypertensive rats. Hypertension 1995; 25:132-138.
21. Bush E, Maeda N, Kuziel WA, Dawson TC, Wilcox JN, Delean H. CC Chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension 2000; 36:360-363.
22. Hilgers KF, Hartner A, Porst M, Mai M, Wittmann M, Hugo C, et al. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int 2000; 58:2408-2419.
23. De la Fuente M, Hernanz A, Vallejo MC. The immune system in the oxidative stress conditions of aging and hypertension: favorable effects of antioxidants and physical exercise. Antioxid Redox Signal 2005; 7:1356-1366.
24. Stewart J, Jung FF, Manning J, Vehaskari VM. Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. Kidney Int 2005; 68:2180-2188.
25. Pfab T, Chen YP, Slowinski T, Richter CM, Godes M, Arck PC, et al. Impact of gene related to immune tolerance and inflammation on blood pressure, protein excretion and oedema in pregnancy. J Hypertens 2005; 23:2187-2191.
26. Brush JE, Faxon DP, Salmon S, Jacobs AK, Rugan TJ. Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol 1992; 19:809-815.
27. Sinisalo J, Paronen J, Mattila KJ, Syrjala M, Alfthan G, Palosuo T. Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis 2000; 149:403-411.
28. Kampus P, Muda P, Kals J, Ristimae T, Fischer K, Teesalu R, et al. The relationship between inflammation and arterial stiffness in patients with essential hypertension. Int J Cardiol 2005; 15:2443-2449.
29. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46:1118-1122.
30. Madej A, Okopien B, Kowalski J, Haberka M, Herman ZS. Plasma concentration of adhesion molecules and chemokines in patients with essential hypertension. Pharmacol Rep 2005; 57:878-881.
31. Sonmez A, Dogru T, Yilmaz MI, Ocal R, Ozgurtas T, kilic S, et al. Soluble CD40 ligand levels in patients with hypertension. Clin Exp Hypertens 2005; 27:629-634.
32. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults: the CARDIA Study. Arch Intern Med 2006; 166:345-349.
33. Rodriguez-Iturbe B, Quiroz Y, Kim CH, Vaziri DN. Hypertension induced by aortic coarctation above the renal arteries is associated with immune cell infiltration of the kidneys. Am J Hypertension 2005; 18:1449-1456.
34. Lim HS, Lip GY. Interleukin-15 in hypertension: future insights into inflammation and vascular disease. Am J Hypertens 2005; 18:1017-1018.
35. Kaibe M, ohishi M, Ito N, Yuan M, Takagi T, Terai M, et al. Serum interleukin-15 concentration in patients with essential hypertension. Am J Hypertens 2005; 18:1019-1025.
36. Kon KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006; 108:96-100.
37. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005;46: 735-739.
38. Agabiti Rosei E, Morelli P, Rizzoni D. Effects of nifedipine GIT 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension. Blood Press Suppl 2005;1:14-22.
39. Toba H, Nakagawa Y, Miki S, Shimizu T, Yoshimura A, Inoue R, et al. Calcium channel blockers exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitric-L-NAME induced hypertensive rat aorta. Hypertension Res 2005; 28:689-700.